EC gives marketing approval for radium-223 in metastatic CRPC


We understand that, earlier today, the European Commission (EC) approved radium-223 dichloride (Xofigo®) for the treatment of men with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastases.

Radium-223 was approved for essentially the same indication in the USA back in May this year. The actual availability of this drug to most patients in individual European nations may take some time while governments negotiate pricing with the manufacturers. A media release issued by Bayer is available on line.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: